2026-525543-32-00RecruitingPhase 1
A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 May 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 13 Mar 2026
- Start date
- 17 Jun 2026
- Lead sponsor
- Oncopeptides AB
- Diseases
- Glioblastoma
- EU CT number
- 2026-525543-32-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 10
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a glioblastoma that has come back and who are already scheduled for surgery. It studies how a single dose of melflufen reaches the tumour tissue.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Recurrent (returning) glioblastoma, with surgery already planned
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oslo Universitetssykehus HF | Oslo | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.